ARV-trial.com Switch to MVC MARCH Study 1.

Slides:



Advertisements
Similar presentations
Switch to TDF/FTC/RPV - SPIRIT Study. SPIRIT study: switch PI/r + 2 NRTI to TDF/FTC/RPV STR  Design TDF/FTC/RPV STR 24 weeks 48 weeks Primary Endpoint.
Advertisements

Switch to ATV/r + RAL  HARNESS Study. ATV/r 300/100 mg qd + TDF/FTC N = 37 N = 72 ATV/r 300/100 mg qd + RAL 400 mg bid  Design Randomisation 2: 1 Open-label.
Switch to TDF/FTC/RPV  SPIRIT Study. SPIRIT study: Switch PI/r + 2 NRTI to TDF/FTC/RPV TDF/FTC/RPV STR 24 weeks 48 weeks Primary Endpoint Secondary Endpoint.
Switch to ATV/r + 3TC  SALT Study. ATV/r 300/100 mg qd + 2 NRTI (investigator-selected) N = 143 ATV/r 300/100 mg + 3TC 300 mg qd  Design Randomisation*
Switch to ATV/r-containing regimen  ATAZIP. Mallolas J, JAIDS 2009;51:29-36 ATAZIP ATAZIP Study: Switch LPV/r to ATV/r  Design  Endpoints –Primary:
Comparison of PI vs PI  ATV vs ATV/r BMS 089  LPV/r mono vs LPV/r + ZDV/3TCMONARK  LPV/r QD vs BIDM M A5073  LPV/r + 3TC vs LPV/r + 2 NRTIGARDEL.
Comparison of NNRTI vs NNRTI  ENCORE  EFV vs RPV –ECHO-THRIVE –STAR  EFV vs ETR –SENSE.
Switch to DRV/r monotherapy  MONOI  MONET  PROTEA  DRV600.
Switch to ATV ± r-containing regimen  SWAN Study  SLOAT Study.
Switch to PI/r monotherapy
Comparison of PI vs PI ATV vs ATV/r BMS 089
ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.
NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN
Switch to PI/r + 3TC vs PI/r monotherapy
ARV-trial.com Switch to ATV/r + 3TC ATLAS-M Study.
ARV-trial.com Switch to D/C/F/TAF EMERALD Study 1.
Switch to DTG + RPV Switch to DTG + RPV SWORD Study
ARV-trial.com Switch to LPV/r + RAL KITE Study 1.
Switch ABC/3TC to TAF/FTC
Switch to DTG + 3TC ASPIRE Study.
Switch from TDF to TAF GS-US Study GS-US Study
NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN
Switch to DTG-containing regimen
Comparison of NNRTI vs NNRTI
Switch to DRV/r + 3TC DUAL Study.
Comparison of NNRTI vs NNRTI
Switch to BIC/FTC/TAF GS-US GS-US GS-US
Comparison of PI vs PI ATV vs ATV/r BMS 089
Switch to E/C/F/TAF + DRV
Switch to LPV/r monotherapy
Switch to D/C/F/TAF EMERALD Study.
Switch to BIC/FTC/TAF GS-US GS-US GS-US
Switch to DRV/r monotherapy
Switch to LPV/r monotherapy
Comparison of NNRTI vs PI/r
Comparison of PI vs PI ATV vs ATV/r BMS 089
Switch ABC/3TC to TDF/FTC
Comparison of NRTI combinations
Comparison of PI vs PI ATV vs ATV/r BMS 089
Comparison of PI vs PI ATV vs ATV/r BMS 089
Switch to LPV/r monotherapy
Switch to ATV- or ATV/r-containing regimen
Comparison of PI vs PI ATV vs ATV/r BMS 089
Switch to RAL-containing regimen
Comparison of NNRTI vs NNRTI
ARV-trial.com Switch to DRV/r + RPV PROBE Study 1.
Comparison of NNRTI vs PI/r
Comparison of NRTI combinations
Switch to RAL-containing regimen
Switch to BIC/FTC/TAF GS-US GS-US GS-US
Comparison of PI vs PI ATV vs ATV/r BMS 089
ARV-trial.com Switch to TDF/FTC/EFV AI Study 1.
Comparison of NNRTI vs NNRTI
Switch to DTG-containing regimen
NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN
Switch to DTG + RPV Switch to DTG + RPV SWORD Study
Switch to ATV/r monotherapy
Comparison of NRTI combinations
NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN
Switch to LPV/r monotherapy
ARV-trial.com Switch to ATV/r + RAL HARNESS Study 1.
ARV-trial.com Switch to DTG/ABC/3TC STRIIVING NEAT
Comparison of NRTI combinations
Comparison of NRTI combinations
Comparison of PI vs PI ATV vs ATV/r BMS 089
NRTI-sparing SPARTAN PROGRESS RADAR NEAT001/ANRS 143 A VEMAN
ARV-trial.com Switch to FTC + ddI + EFV ALIZE 1.
Comparison of NNRTI vs NNRTI
Comparison of PI vs PI ATV vs ATV/r BMS 089
Comparison of NNRTI vs NNRTI
Presentation transcript:

ARV-trial.com Switch to MVC MARCH Study 1

MARCH Study: switch to MVC Design Randomisation 1 : 2 : 2 Open-label W48 W96 Adults ≥ 18 years Stable (> 24 weeks) 2 NRTI + PI/r regimen HIV RNA < 200 c/mL CCR5 virus on proviral DNA tropism testing No previous virological failure No resistance to study medications HBs Ag negative N = 82 Continuation of 2 NRTI + PI/r N = 156 2 NRTI + MVC 300 mg BID N = 157 PI/r + MVC 150 mg BID Objective Primary Endpoint: proportion with HIV RNA < 200 copies/mL at W48 Non inferiority of the switch arms vs control, by intention-to-treat, lower margin of the two-sided 95% CI for the difference = - 12 %, 80 % power MARCH Pett SL. Clin Infect Dis 2016;63:122-32

MARCH Study: switch to MVC Baseline characteristics and disposition 2 NRTI + PI/r N = 82 2 NRTI + MVC N = 156 PI/r + MVC N = 157 Mean age, years 43.6 43.7 42.7 Female, % 24 22 CDC, category C, % 25.6 23.1 19.1 Baseline HIV RNA < 50 c/mL, % 96.3 96.8 95.5 Baseline CD4/mm3, mean 635 596 638 Nadir CD4/mm3, mean 258 206 238 ART duration, mean years 6.3 5.7 6.4 Baseline ART, % TDF/FTC ; TDF+3TC ; ABC/3TC ; ZDV/3TC ATV/r ; LPV/r ; DRV/r ; SQV/r 46 ; 16 ; 22 ; 7 33 ; 35 ; 16 ; 11 53 ; 17 ; 12 ; 13 37 ; 21 ; 21 ; 15 53 ; 16 ; 13 ; 11 35 ; 32 ; 13 ; 14 Mean Framingham 10-year CVD risk 6.87 6.84 Discontinuation at W48, N Not on randomised ART Lost to follow-up Withdrew Died 2 1 16 13 17 MARCH Pett SL. Clin Infect Dis 2016;63:122-32

MARCH Study: switch to MVC Virologic Outcomes – W48 Intention to Treat Analysis 100 95.1 91.7 20 40 60 80 % HIV RNA < 50 c/mL HIV RNA < 200 c/mL (primary endpoint) 97.6 93.6 * 77.7 84.1 ** 2 NRTI + MVC 2 NRTI + PI/r PI/r + MVC * ≠ : - 4% ; (95% CI = - 9.0 to 2.2) ** ≠ : - 13.5% ; (95% CI = - 19.8 to -5.8) MARCH Pett SL. Clin Infect Dis 2016;63:122-32

MARCH Study: switch to MVC % with virologic response (HIV RNA < 200 c/mL), by week Hazard ratio for loss of virological response < 200 c/mL over 48 weeks: 2.41 (95% CI: 1.31-4.43 ; p = 0.005) for the MVC + PI/r arm vs control arm 2 NRTI + MVC 2 NRTI + PI/r PI/r + MVC 0.00 1.00 0.25 0.50 0.75 12 24 36 48 60 72 84 96 Week Number at risk 2 NRTI + PI/r 2 NRTI + MVC PI/r + MVC 82 156 157 81 149 151 80 143 137 80 139 134 77 132 123 59 103 98 45 90 65 36 86 54 17 60 36 MARCH Pett SL. Clin Infect Dis 2016;63:122-32

MARCH Study: switch to MVC Emergent resistance in participants with confirmed virologic failure 2 NRTI + PI/r N = 82 2 NRTI + MVC N = 156 PI/r + MVC N = 157 Confirmed virologic failure, N 1 6 18 Successful sequencing, N 5 17 PI and RT genotype R emergence (mutations) N = 1 - K103N N = 5 - M41L, T215E - M184V, K101E, Y181C, G190A - L10I, K65R, V106I - L10I, A71V, M184V - L90M, L10I, A71V, M184M/V N = 7 - L10I - I50V, L10I, L33F/L - A62V, T215S - K20I - E138A - V32A/V Tropism (phenotypic assessment) at failure CCR5 CXCR4 Test failed 4 10 3 4 MARCH Pett SL. Clin Infect Dis 2016;63:122-32

MARCH Study: switch to MVC Changes in immunologic and metabolic parameters and quality of life over 48 weeks Mean change 2 NRTI + PI/r N = 82 2 NRTI + MVC N = 156 PI/r + MVC N = 157 CD4/mm3 increase + 40 + 39 + 29 Total cholesterol, mmol/L + 0.06 - 0.45 p < 0.0001 + 0.34 HDL-cholesterol, mmol/L + 0.05 + 0.04 + 0.10 LDL-cholesterol, mmol/L - 0.27 p ≤ 0.0002 + 0.18 Triglycerides, mmol/L - 0.0795 - 0.4016 + 0.1146 Lumbar spine, T-score - 0.05 + 0.08 p = 0.03 + 0.10 p = 0.028 Right hip, T-score - 0.12 - 0.12 ns + 0.07 p = 0.01 Physical and mental QOL No significant changes vs control p: vs 2 NRTI + PI/r MARCH Pett SL. Clin Infect Dis 2016;63:122-32

MARCH Study: switch to MVC Safety at W48 2 NRTI + PI/r N = 82 2 NRTI + MVC N = 156 PI/r + MVC N = 157 Mean changes in GFR, mL/min -1.96 - 9.54 - 0.69 Discontinuation for adverse event, N 1 4 Serious adverse event, N (%) 8 (9.76) 15 (9.62) 14 (8.92) One myocardial infarction was reported on MVC in a patient with increased CVD risk due to lifestyle and cardiac congenital malformation MARCH Pett SL. Clin Infect Dis 2016;63:122-32

MARCH Study: switch to MVC Conclusion This large international randomised study demonstrates that MVC with a 2-N(t)RTI backbone, in those with R5-tropic virus determined by genotypic tropism testing, is a switch/simplification option for patients virologicaly suppressed on PI/r + N(t)RTI regimens MVC was safe and well tolerated, with favorable impact on lipids and neutral effects on renal function over 48 weeks These data support MVC as a switch option for ritonavir-boosted PIs when partnered with a 2-N(t)RTI backbone, but not as part of N(t)RTI-sparing regimens comprising MVC with PI/r MARCH Pett SL. Clin Infect Dis 2016;63:122-32